Synonym
FF-10502; 4'-Thio-fac; 184302-49-6; FF 10502; FF10502
IUPAC/Chemical Name
4-amino-1-((2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one
InChi Key
NIDPJRZOVFIBQB-PXBUCIJWSA-N
InChi Code
InChI=1S/C9H12FN3O3S/c10-6-7(15)4(3-14)17-8(6)13-2-1-5(11)12-9(13)16/h1-2,4,6-8,14-15H,3H2,(H2,11,12,16)/t4-,6+,7-,8-/m1/s1
SMILES Code
NC1=NC(=O)N(C=C1)[C@@H]2S[C@H](CO)[C@@H](O)[C@@H]2F
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
261.27
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Zajchowski DA, Biroc SL, Liu HL, Chesney SK, Hoffmann J, Bauman J, Kirkland
T, Subramanyam B, Shen J, Ho E, Tseng JL, Dinter H. Anti-tumor efficacy of the
nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine
(4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models. Int J
Cancer. 2005 May 10;114(6):1002-9. doi: 10.1002/ijc.20835. PMID: 15645422.
2: Miura S, Izuta S. DNA polymerases as targets of anticancer nucleosides. Curr
Drug Targets. 2004 Feb;5(2):191-5. doi: 10.2174/1389450043490578. PMID:
15011952.
3: Miura S, Yoshimura Y, Endo M, Satoh H, Machida H, Sasaki T. Comparison of
1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in
its antitumor activity. Cancer Lett. 1999 Oct 1;144(2):177-82. doi:
10.1016/s0304-3835(99)00221-9. PMID: 10529018.
4: Miura S, Endo Y, Yoshimura Y, Endo M, Yonemura Y, Sasaki T. Potent antitumor
effect of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine on
peritoneal dissemination models of gastrointestinal cancers. Oncol Rep. 2002
Nov-Dec;9(6):1319-22. PMID: 12375041.
5: Miura S, Yoshimura Y, Satoh H, Izuta S. The antitumor mechanism of
1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)-cytosine: effects of its
triphosphate on mammalian DNA polymerases. Jpn J Cancer Res. 2001
May;92(5):562-7. doi: 10.1111/j.1349-7006.2001.tb01130.x. PMID: 11376566; PMCID:
PMC5926742.
6: Miura S, Yoshimura Y, Endo M, Machida H, Matsuda A, Tanaka M, Sasaki T.
Antitumor activity of a novel orally effective nucleoside,
1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine. Cancer Lett. 1998
Jul 3;129(1):103-10. doi: 10.1016/s0304-3835(98)00089-5. PMID: 9714341.
